Trial Profile
A Phase 1/2 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients With Myelodysplastic Syndrome (RAEB-2) or With Previously Untreated Acute Myeloid Leukemia.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Refractory anaemia with excess of blasts
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2020 Status changed from active, no longer recruiting to completed.
- 02 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 22 Jul 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.